Ceska Gynekol. 2022;87(5):328-332. doi: 10.48095/cccg2022328.
Manifestation of ovarian carcinoma in the form of inguinal lymph node involvement represents a rare clinical situation described only by a limited number of case reports. Similarly, extraperitoneal dissemination of the tumor in the absence of advanced abdominal disease is uncommon. We report a 58-year-old female patient with a positive family history of ovarian cancer referred for lymph node enlargement in the left groin and elevation of CA 125. An ultrasound examination of the patients left groin revealed an enlarged lymph node of a size 4 × 3cm, the bio-psy of which confirmed a metastatic adenocarcinoma with origin in the female genital area (müllerian epithelium). The finding was suggestive of high-grade endometroid carcinoma. The patient subsequently underwent a PET/CT, with lesions suspect for the presence of viable malignant tissue in the left ovary (which was of normal size) and a lymph node conglomeration in the left groin. The patient was indicated for a radical cytoreductive surgery resulting in no macroscopic residual disease. Definitive histological examination confirmed high-grade endometroid adenocarcinoma of the left fallopian tube of histopathological stage FIGO IVB pT2b pN0 (17/0) pM1 (inguinal lymph node). The patient was dia-gnosed with somatic BRCA1 mutation. The patient was indicated for adjuvant chemotherapy with paclitaxel/carboplatin, 16 cycles were administered, and for subsequent maintenance therapy with PARP inhibitor. Currently, one year after the primary cytoreductive procedure, the patient is in complete remission of the disease.
卵巢癌表现为腹股沟淋巴结受累的形式,这种临床表现较为罕见,仅在少数病例报告中有所描述。同样,肿瘤腹膜外播散而无晚期腹部疾病也不常见。我们报告了一位 58 岁女性患者,有卵巢癌阳性家族史,因左腹股沟淋巴结肿大和 CA125 升高而就诊。患者左腹股沟的超声检查显示一个 4×3cm 大小的淋巴结肿大,活检证实为起源于女性生殖区(米勒上皮)的转移性腺癌。这一发现提示为高级别子宫内膜样癌。随后患者进行了 PET/CT 检查,左卵巢(大小正常)和左腹股沟有疑似存在存活恶性组织的病变,且有一个淋巴结聚集。患者需要进行根治性细胞减灭术,结果无肉眼残留疾病。明确的组织学检查证实为左侧输卵管高级别子宫内膜样腺癌,FIGO 分期为 IVB 期 pT2b pN0(17/0)pM1(腹股沟淋巴结)。患者被诊断为体细胞 BRCA1 突变。患者接受紫杉醇/卡铂辅助化疗,共进行了 16 个周期,随后接受 PARP 抑制剂维持治疗。目前,在初次细胞减灭术后一年,患者疾病完全缓解。